Wire · opportunities
Novartis' centerpiece of $12B Avidity buyout flunks 'crucial' phase 3 test
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 8 September 2026 · Fusion42 review
Novartis' antibody oligonucleotide conjugate del-desiran failed to meet the primary endpoint in a pivotal phase 3 trial for myotonic dystrophy type 1, undermining expectations for the $12 billion Avidity Biosciences acquisition. This setback clouds the drug’s contribution to future sales, prompting Novartis to reassess development plans with health authorities.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You need to rethink your biotech pipeline if it leans on late-stage neuromuscular assets like del-desiran. The biggest prize in Novartis’ Avidity buyout just stumbled, opening room for competitors to capture orphan disease markets you target.
◆ Coverage
1 source · 8 Sep 2026
◆ Related on Wire
◆ Topics